Viewing Study NCT01868451

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:39 PM
Ignite Modification Date: 2026-02-25 @ 2:41 AM
Study NCT ID: NCT01868451
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-07-09
First Post: 2013-05-30
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hodgkin Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None DACARBAZINE View
None DOXORUBICIN/ADRIAMYCIN View
None SGN-35 (BRENTUXIMAB VEDOTIN) View
None VINBLASTINE View
None Involved-site radiation therapy (ISRT) View
None Early stage View
None 13-034 View